Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Hoth Therapeutics Inc (NASDAQ: HOTH) has entered into a Research Agreement with the University of Cincinnati Research Institute to perform critical antimicrobial characterization studies with HT-006 as part of the streamlined drug development plan.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
- HT-006 is under development as a potential treatment for multi-drug resistant bacterial lung infections, such as hospital-acquired pneumonia, cystic fibrosis, chronic obstructive pulmonary disease, and ventilator-associated pneumonia.
- Hoth previously licensed the HT-006 technology for commercial evaluation from the Walter Reed Army Institute of Research.
- The research plan includes critical antimicrobial in vitro characterization studies for HT-006 in alignment with the FDA's program for "antibacterial therapies.
- The company says that this streamlined program allows for nonclinical animal studies to reduce clinical studies required for approval.
- Price Action: HOTH gained 3.3% at $2.19 in market trading hours on the last check Wednesday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.